Health Care Archives - Page 427 of 478

1 minute read

Connect Biopharma’s Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile

August 30, 9:36 AM

Connect Biopharma Holdings Limited (NASDAQ:CNTB) has completed its first-in-human Phase 1 study of CBP-174 in healthy adults. CBP-174, a highly selective,…

CNTB

1 minute read

Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold

By Vandana Singh

August 30, 8:52 AM

The FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of Emavusertib.

CRIS

1 minute read

Becton Dickinson To Pay $4.8M In Hernia Mesh Lawsuit, Second Within Six Months

By Vandana Singh

August 30, 7:49 AM

Becton Dickinson and Co's (NYSE: BDX) unit, C.R. Bard Inc, was ordered to pay $4.8 million in a lawsuit related to its hernia repair mesh. The company faces more than 30,000 similar lawsuits over its mesh hernia repair devices.

BDX

1 minute read

Sanofi’s Hemophilia Candidate Goes Under Priority FDA Review

By Vandana Singh

August 30, 6:46 AM

The FDA has accepted for priority review Sanofi SA’s (NASDAQ:SNY) marketing application for efanesoctocog alfa (BIVV001) for hemophilia A, a rare…

BIOVF

1 minute read

Cathie Wood Loads Up $3M In This Precision Medicine Firm’s Shares Despite Bleak Q2 Results

By Bhavik Nair

August 30, 6:12 AM

Cathie Wood-led Ark Investment Management loaded up on 153,917 shares of precision medicine company CareDx Inc (NASDAQ: CDNA), via the ARK Genomic Revolution ETF (NYSE: ARKG<

ARKG

2 minute read

‘Man Who Solved The Market,’ Quant Legend James Simons, Last Held These Two Dividend Stocks

By Robert Kuczmarski

August 29, 4:50 PM

Jim Simons is the founder of Renaissance Technologies, which uses a quantitative strategy when buying and selling out of positions.

ABB

1 minute read

This Small Cap Cancer Stock Gets An Upgrade And Price Target Bump On ‘Clinical Programs Progress’

By Vandana Singh

August 29, 3:52 PM

HC Wainwright updated its model on Calithera Biosciences Inc (NASDAQ:CALA), reflecting the recent Q2 earnings with no revenues and a net loss of…

CALA

1 minute read

This Analyst Cuts ChromaDex’s Price Target On Revised Growth Trajectory

By Vandana Singh

August 29, 3:07 PM

Earlier this month, ChromaDex Corp (NASDAQ:CDXC) released Q2 earnings, indicating high single-digit revenue growth for FY22, driven by its global e-commerce…

CDXC